Nanobiotix (NBTX) has released an update.
Nanobiotix, a biotech company specializing in physics-based cancer treatments, will host a virtual event on June 18, 2024, discussing the promising results of their NBTXR3 product combined with immunotherapy in treating head and neck cancer. Renowned KOLs will review the encouraging data from the recent ASCO meeting, showcasing NBTXR3’s ability to control disease and induce tumor response in patients. The event aims to address unmet needs in cancer treatment and explore NBTXR3’s mechanisms of action, local and systemic responses.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
